Loskog Angelica S I, Eliopoulos Aristides G
Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, Uppsala, Sweden.
Semin Immunol. 2009 Oct;21(5):301-7. doi: 10.1016/j.smim.2009.07.001. Epub 2009 Jul 31.
CD40 is a TNF receptor family member that is widely recognized for its prominent role in immune regulation and homeostasis. Expression of CD40 is not restricted to normal lymphoid cells but is also evident in the majority of haemopoietic and epithelial malignancies where it has been implicated in oncogenic events. Accumulating evidence, however, suggests that the CD40 pathway can be exploited for cancer therapy by virtue of its ability to stimulate the host anti-tumor immune response, normalize the tumor microenvironment and directly suppress the growth of CD40-positive tumors. Here, we provide an overview of the multifaceted functions of the CD40 pathway in cancer and its emerging role in the treatment of malignancy.
CD40是肿瘤坏死因子受体家族成员,因其在免疫调节和内环境稳定中的突出作用而被广泛认可。CD40的表达不仅限于正常淋巴细胞,在大多数造血和上皮恶性肿瘤中也很明显,它与致癌事件有关。然而,越来越多的证据表明,CD40通路可因其刺激宿主抗肿瘤免疫反应、使肿瘤微环境正常化以及直接抑制CD40阳性肿瘤生长的能力而被用于癌症治疗。在此,我们概述了CD40通路在癌症中的多方面功能及其在恶性肿瘤治疗中的新作用。